Mr. Tobin was previously N2 Biomedical’s COO, the release said. He has more than 30 years of experience with the company and its corporate parent.
“I am truly honored that the Board has selected me to assume the CEO position and am excited about the prospects for the company’s future,” Mr. Tobin said in the release. “We have a dedicated and talented staff, a great foundation of core technologies, and a solid customer base. I look forward to working with the Board and Ampersand to continue providing our customers with the high level of service that they’ve come to expect from us while also building upon our numerous strengths as a company and capitalizing on growth opportunities.”
Read the full press release here.
More articles on biologics:
2 CEOs on orthopedic consolidation — Don’t grow for the sake of growth alone
Zimmer Biomet seals $250M acquisition of medical device company
175+ spine, orthopedic surgeons on the move in 2020
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
